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Introduction
Migraine is a common, disabling neurological problem the precise pathogenesis of which remains to be delineated. It is likely that activation of trigeminal afferents innervating dural structures is involved in the headache phase of migraine (Goadsby et al., 2002) . Stimulation of dural sites is painful in humans (Ray and Wolff, 1940) and activation of trigeminal neurons in animal studies causes calcitonin gene-related peptide (CGRP) release (Goadsby et al., 1988) and dural blood vessel dilation (Williamson et al., 1997b) . Both the CGRP release (Goadsby and Edvinsson, 1993) and dural blood vessel dilation (Williamson et al., 1997b) are inhibited by the triptans, serotonin, 5-HT 1B/1D receptor agonists, which are potent anti-migraine compounds (Ferrari et al., 2001) . Recent clinical trial evidence suggests that blockade of CGRP receptors has a potent acute anti-migraine effect (Olesen et al., 2004) .
As well as the headache phase in migraine there are also the premonitory and resolution phases, that are characterised by nausea, vomiting, hypotension and drowsiness, tiredness and mood changes, respectively (Headache Classification Committee of The International Headache Society, 2004) . Given that these changes may be a result of monoamine, and specifically dopaminergic neurotransmission, dopamine has been implicated in migraine (Peroutka, 1997; Mascia et al., 1998; JPET#83139 domperidone can prevent the occurrence of migraine if it is taken during the premonitory phase (Amery and Waelkens, 1983; Waelkens, 1984) . This has led to a dopamine theory of migraine.
Studies performed on cat pial arteries in vivo and middle cerebral arteries in vitro showed that at very low doses dopamine agonists caused slight vasodilation, while at higher doses dopamine caused vasoconstriction (Edvinsson et al., 1978a; Edvinsson et al., 1978b) . Similarly, dopamine and apomorphine intra-carotid infusions caused a dose-dependent vasoconstriction in dog (Villalon et al., 2003) , although they found that a selective D 1 -receptor agonist caused slight vasodilation, as did the effects of dopamine after it was antagonised by a α 2 -adrenergic receptor antagonist.
Given the effects of dopamine on the cerebral, pial and carotid arteries, as well as the renal and mesenteric vasculature we wanted to examine what effects dopamine might have on the dural vasculature, and therefore, whether it may be involved in any direct way, in the headache phase of migraine. The intravital microscopy model of trigeminovascular activation utilises the reaction of meningeal blood vessel calibre after electrical stimulation of a cranial window, as a model of trigeminal nerve fibre activation (Williamson et al., 1997b) , and it has proved to be an excellent model in predicting anti-migraine efficacy (Williamson et al., 1997b) . Previously the triptans have been shown to attenuate neurogenic dural vasodilation (Williamson et al., 1997b) . We looked at the effects of dopamine agonists and antagonists on neurogenic dural vasodilation. We also looked at the direct effects of dopamine and specific D 1 and D 2 receptor agonists on dural blood vessel calibre. The response of dopamine was also challenged with specific dopamine receptor antagonists, as well as α 2 -JPET#83139 7 adrenoceptor antagonists. We monitored carefully any changes in arterial blood pressure related to dopamine and the various antagonists.
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Materials and Methods
Surgical Preparation
All experiments were conducted under the UK Home Office (Scientific Procedures) Act (1986) . Male Sprague-Dawley rats (280-385 g) were anaesthetised throughout the experiments with sodium pentobarbitone (60mgkg -1 i.p. initially and then 18mgkg -1 hri.v. infusion). The left femoral artery and vein were cannulated for blood pressure recording and intravenous infusion of anaesthetic, respectively. Temperature was maintained throughout using a homeothermic blanket system. The rats were placed in a stereotaxic frame, the skull exposed and the right or left parietal bone thinned by drilling with a saline-cooled drill until the blood vessels of the dura mater were clearly visible through the intact skull.
Intravital Microscopy
The cranial window was covered with mineral oil (37 o C) and a branch of the middle meningeal artery viewed using an intravital microscope (Microvision MV2100, UK) and the image displayed on a television monitor. Dural blood vessel diameter was continuously measure using a video dimension analyser (Living Systems Instrumentation, USA) and displayed with blood pressure on a data analysis system (Spike2 v4, Cambridge Electronic Design, Cambridge UK).
Experimental Protocols
Defining electrical stimulation parameters. 
Data Analysis
The peak effects of electrical stimulation and dopamine infusion on dural vessel 
Results
Effects of dopamine and dopamine receptor antagonist of neurogenic dural vasodilation
Neurogenic dural vasodilation with electrical stimulation was significantly inhibited when compared to control during infusion of 20 µgkg -1 min -1 dopamine, 116.7 ± 14 % to 46 ± 9 % (n = 11, t 10 = 6.78, P < 0.05), an uninhibited vasodilation was restored post dopamine infusion, 46 ± 9 % to 111.2 ± 8 % (n = 11, t 10 = -7.98, P < 0.05). This is similarly the case for the 40 µgkg -1 min -1 dopamine infusion, vasodilation was inhibited from 145.1 ± 15 % to 76.3 ± 12 % (n = 7, t 6 = 3.92, P < 0.05), and the full vasodilation was restored post dopamine infusion, 76.3 ± 12 % to 137.5 ± 20 % (n = 7, t 6 = 2.93, P < 0.05; Figure 1A ). Specific dopamine receptor agonists were also infused, A68930 hydrochloride (50 µgkg -1 min -1 ) was able to significantly inhibit neurogenic dural vasodilation from 102.0 ± 8 % to 42.3 ± 14 % (n = 6, t 5 = 3.46, P < 0.05) and the neurogenic dural vasodilation response returned post A68930
hydrochloride infusion, 42.3 ± 14 % compared to 93.0 ± 14 % (n = 6, t 5 = -2.82, P < 0.05). The neurogenic dural vasodilator response after (-)-quinpirole hydrochloride (50 µgkg -1 min -1 ) was not significant, 97.3 ± 9 % compared to 94.5 ± 13 % (n = 6, t 5 = 0.43, P = 0.685).
The dopamine hydrochloride induced inhibition of neurogenic dural vasodilation was blocked by pre-treatment with the α 2 -adrenergic receptor antagonist yohimbine (3 mgkg -1 ), 31.4 ± 8 % compared to 72.5 ± 8 % (n = 6, t 5 = 2.26, P = 0. 31.4 ± 8 % compared to 35.0 ± 6 % (n = 6, t 5 = 9.99, P < 0.05), see figure 1B. The A68930 hydrochloride induced inhibition of neurogenic dural vasodilatation was also reversed by yohimbine (3 mgkg -1 ), 24.49 ± 9 % compared to 102.6 ± 4 % (n = 5, t 4 = -6.15, P < 0.05), see figure 2.
None of the dopamine receptor antagonists were able to inhibit neurogenic dural vasodilation at the doses applied, data are summarised in table 2 and figure 3. The effects of the dopamine antagonists themselves on dural blood vessel diameter and mean arterial blood pressure are summarised in table 4. In each case where significant changes in dural blood vessel diameter occurred, the baseline vessel diameter was restored naturally before a repeat electrical stimulation.
Effect of dopamine hydrochloride and D 1 and D 2 receptor agonists on dural blood vessel diameter and mean arterial blood pressure
In rats treated with dopamine hydrochloride (0.5, 1, 2, 5, 10, 15, 20 and 40 µgkg -1 min -1 ), there was no significant effect on dural vessel diameter across all doses using an ANOVA for repeated measures (n = 6, F 7,35 = 1.423, P = 0.288), although using a Student's paired t-test both the 20 (t 16 = 3.8, P < 0.05) and 40 µgkg -1 min -1 (t 39 = 7.9, P < 0.05) doses were significant, in all animals tested (Table 3 ). The slight change in dural blood vessel diameter was accompanied by a significant increase in blood pressure across all doses (n = 6, F 7,35 = 16.667, P < 0.0001). 0.05) and 40 µgkg -1 min -1 (t 39 = -11.62, P < 0.05) doses were significant when compared to the pre-injection blood pressure (Table 3 ).
A68930 hydrocloride (1, 10 and 50 µgkg -1 ) did not cause any significant change to the dural blood vessel diameter across the cohort (n = 6, F 2,10 = 2.3, P = 0.175), however using Student's paired t-test both 10 (t 5 = 4.5, P < 0.05) and 50 µgkg -1 (t 13 = 3.85, P < 0.05) proved significant in all animals tested. There was a significant change in arterial blood pressure overall (n = 6, F 2,10 = 27.6, P < 0.05). The blood pressure change with the 50 µgkg -1 dose of A68930 hydrochloride proved to be significant (t 13 = -7.88, P < 0.05). (-)-Quinpirole hydrochloride (1, 10 and 50 µgkg -1 ) did not cause any significant change in both dural blood vessel diameter (n = 6, F 2,10 = 0.381, P = 0.63) or arterial blood pressure (n = 6, F 2,10 = 2.78, P = 0.137), these data are summarised in table 4.
Effects of dopamine receptor antagonists and a α 2 -adrenergic receptor antagonist on blood vessel diameter and mean arterial blood pressure changes caused by dopamine
The effects of 40 µgkg was a 46.2 ± 6 mmHg compared to 34.1 ± 6 mmHg decrease in mean arterial blood pressure (t 5 = 3.05, P = 0.028, n = 6).
S(-)-eticlopride hydrochloride, the D 2 receptor antagonist had no significant effect on the dopamine-induced changes to dural blood vessel diameter (F 3,18 = 0.282, P = 0.682, n = 7) or mean arterial blood pressure (F 3,18 = 3.857, P = 0.06, n = 7).
U99194A maleate, the D 3 receptor antagonist had no significant effect on the dopamine-induced changes to dural blood vessel diameter (F 2,10 = 1.404, P = 0.292, n = 6) or mean arterial blood pressure (F 2,10 = 1.401, P = 0.292, n = 6). Finally, in rats treated with L-745,870 hydrochloride, the D 4 receptor antagonist, there was no significant effect on the dopamine-induced changes to dural blood vessel diameter (F 2,12 = 0.279, P = 0.719, n = 7) or mean arterial blood pressure (F 2,12 = 0.714, P = 0.448, n = 7).
Yohimbine (3 mgkg -1 ), the α 2 -adrenergic receptor antagonist, was able to significantly attenuate the dural blood vessel changes caused by 40 µgkg -1 min -1 dopamine infusion, from a 22.2 ± 4% to a 3.3 ± 2% reduction in vessel diameter (n = 7, t 6 = 4.73, P < 0.05). The mean arterial blood pressure changes caused by dopamine infusion were also significant reduced from 29.3 ± 7 mmHg to 2.7 ± 2 mmHg (n = 7, t 6 = 3.54, P < 0.05).
The effects of the D 1 and D 2 dopamine receptor agonists were also challenged with yohimbine (3 mgkg -1
). Yohimbine did not alter the response of A68930 hydrochloride (50 µgkg -1 min -1 ) on dural blood vessel diameter (t 5 = 1.42, P = 0.214, n = 6), but was able to reverse the arterial blood pressure effects from a 40.2 ± 4 mmHg increase to a 10.7 ± 3 mmHg increase (t 5 = 5, P < 0.05, n = 6). Yohimbine did not alter the response of (-)-quinpirole hydrochloride (50 µgkg -1 min -1 ) on dural blood vessel JPET#83139 diameter (t 4 = 0.23, P = 0.828, n = 5) and arterial blood pressure (t 4 = 0.19, P = 0.86, n = 5; Table 4 ). Yohimbine, the α 2 -adrenergic receptor antagonist, caused a significant reduction in mean arterial blood pressure of 34.4 ± 5 mmHg (n = 13, t 12 = 7.51, P < 0.05), this was accompanied by a significant 52.4 ± 18% increase (n = 13, t 12 = 3.41, P < 0.05) in dural blood vessel diameter. Both were naturally restored to their pre-injection levels within the time constraints of the experimental protocol.
Effects of dopamine antagonists and a α
This article has not been copyedited and formatted. The final version may differ from this version. Administration of dopamine hydrochloride and A68930 hydrochloride, the D 1 receptor agonist, we were able to attenuate neurogenic dural vasodilation. Upon cessation of dopamine agonist infusion, repeat electrical stimulation was able to produce a maximum neurogenic vasodilation. In each case this effect was partly antagonised by the α 2 -adrenoceptor antagonist, yohimbine. The dopamine hydrochloride response was also partially attenuated by the D 1 receptor antagonist, SCH23390, although the antagonised response was still significantly less than the control neurogenic dural vasodilation. The D 2 receptor agonist had no effect on neurogenic dural vasodilation. The ability of dopamine hydrochloride to attenuate neurogenic dural vasodilation may in part be explained by the vasoconstrictive effect of dopamine, which we believe to be caused as a response to the profound blood pressure changes. We have established already, and it has been shown previously, the vasoconstriction and blood pressure changes appear to be mediated by a that are known to act on dopamine receptors (Peroutka, 1997; Mascia et al., 1998; Fanciullacci et al., 2000) .
Neurogenic dural vasodilation is believe to result from the pre-synaptic release of CGRP from trigeminal nerve terminals acting on CGRP receptors on the dural blood vessels causing vasodilation (Williamson et al., 1997b) . The data presented suggest that D 1 dopamine receptors may be involved in the control of the dural vasculature on trigeminal nerve endings. It has been shown previously that there is a lack of response on neurogenic dural vasodilation when α 2 -adrenoceptors are manipulated (Akerman et al., 2001) , therefore it seems unlikely that dopamine is activating through prejunctional α 2 -adrenoceptors to exert its inhibitory action in the trigeminovascular system. There is evidence that D 2 dopamine receptors are present in the trigeminal ganglion, using a cDNA probe and hybridisation techniques (Peterfreund et al., 1995) ,
although from the data they may not be transported to peripheral trigeminal nerve doses given in this study, but other studies have used higher dosing regimens. We were primarily interested in a vasodilatory response, and only found a significant vasodilation at the 1 µgkg -1 min -1 dose regimen. We observe that at a lower dose there was no significant dilation and at higher doses we found increasing vasoconstriction, similar to other studies.
It was unexpected that the vasodilatory effect was not clearly dose-dependent, and the vasodilation was not as extensive as that found in other in vivo studies. Indeed vasodilation has been found at much higher doses, also using an intravenous method of entry (Villalon et al., 2003; Polakowski et al., 2004) . Villalon et al (2003) only found a vasodilator effect with dopamine hydrochloride in the presence of a α 2 -adrenoceptor antagonist, we saw no vasodilator effect in the presence of yohimbine in the dural circulation. Previous studies have also shown that a specific D 1 receptor agonist, fenoldopam, was able to cause vasodilation on its own (Villalon et al., 2003; Polakowski et al., 2004) . In our study the specific D 1 receptor agonist caused a significant vasoconstriction in dural blood vessel calibre and a significant increase in arterial blood pressure; these changes were reversed by a α 2 -adrenoceptor antagonist.
The D 2 receptor agonist was unable to significantly alter either blood vessel diameter or mean arterial blood pressure. We conclude that the changes observed in the dural blood vessels and arterial blood pressure are mediated by vascular α 2 -adrenoceptors rather than dopamine receptors.
Dopamine acts as a precursor to the catecholamines noradenaline and adrenaline, which mediate vasoconstriction and blood pressure increase through the α 1 and α 2 -adrenoceptors (Willems et al., 1999) . In the present study dopamine is likely to be This article has not been copyedited and formatted. The final version may differ from this version. acting as a precursor to noradrenaline in this biological system and thus activating the noradrenergic system to cause vasoconstriction and blood pressure increase. Only the 1 mgkg -1 dose of the D 1 dopamine receptor antagonist was able to attenuate the blood pressure increase, but there was still a significant blood pressure increase, the α 2 -adrenoceptor antagonist was able to reverse both the vasoconstriction and the blood pressure changes caused by the highest dose of dopamine hydrochloride.
The action of the dopamine agonist fenoldopam caused mean arterial blood pressure decrease accompanied by a vasodilation (Polakowski et al., 2004) , which conflicts with the findings of A68930 hydrochloride used in the present study, which showed only vasoconstriction and was inhibited by the α 2 -adrenoceptor antagonist. This is similar to the effects of dopamine hydrochloride. The differences in the response of the specific dopamine agonists may represent a difference in their abilities to activate noradrenergic production, it would certainly be interesting to observe the affects of fenoldopam in the system used in this study.
Significant blood pressure changes were caused by all dopamine receptor antagonists at varying doses, and these were variously accompanied by a change in dural blood vessel diameter. Given the role of dopamine as a precursor of both noradrenaline and adrenaline, and given that amines are released to maintain vascular tone, it is possible that the effect of the dopamine antagonists on blood pressure are a response to inhibition of the precursor to adrenergic synthesis, namely dopamine, and the dural blood vessel diameter changes are a response to the change in blood pressure. This seems to be indicated by the lack of inhibitory effect of the dopamine receptor This article has not been copyedited and formatted. The final version may differ from this version. antagonists on dopamine hydrochloride induced changes, while the α 2 -adrenoceptor antagonist had profound inhibitory effects.
Despite the evidence that dopamine receptors may be present in the trigeminovascular system (Peterfreund et al., 1995) , and that dopamine agonists have been found to exacerbate certain types of headache (Levy et al., 2003) , only the D 1 receptor is able to attenuate or inhibit the activation of dural blood vessels or trigeminal neurons, and ↑ 3.12 ± 4.6 ↑ 7.31 ± 2.5* ↓ 1.18 ± 1.8 ↓ 3.14 ± 1.7 ↓ 0.47 ± 2.0 ↓ 5.21 ± 2.5 ↓ 10.1 ± 3* ↓ 16.45 ± 4* Blood pressure increase (mmHg)
1.43 ± 0.8 0.08 ± 1.5 0.19 ± 1.0 0.09 ± 1.0 3.34 ± 1.6 9.53 ± 2.8* 19.21 ± 3.1* 24.4 ± 3.6* *P < 0.05 significant change compared to status prior to dopamine injection. ↑ increase, ↓ decrease. ↓ 2.58 ± 4 ↓ 17.8 ± 4* ↓ 19.1 ± 6* ↓ 11.3 ± 2 ↓ 4.6 ± 3 ↓ 1.2 ± 3 ↓ 0.86 ± 2 ↑ 1.4 ± 4
Blood pressure change (mmHg) ↑ 4 ± 2 ↑ 9.8 ± 4 ↑ 31.9 ± 4* ↑ 10.7 ± 3*# ↓ 1.1 ± 1 ↑ 0.1 ± 1 ↑ 1.58 ± 1 ↑ 2.2 ± 1 *P < 0.05 significant change compared to status prior to dopamine injection. #P < 0.05 significant change when compared to change with just 50 µgkg -1 A68930 ↑ increase, ↓ decrease. ) ↓ 1.6 ± 6 (t 11 = 1.01, P = 0.295) ↑ 9.3 ± 3* (t 11 = 3.34, P < 0.05) U99194A (1.0 mgkg -1 ) ↓ 10.3 ± 3* (t 11 = 2.98, P < 0.05) ↑ 8.4 ± 3* (t 11 = 2.97, P < 0.05) U99194A (3.0 mgkg -1 ) ↓ 10.7 ± 8 (t 11 = 1.47, P = 0.17) ↑ 10.5 ± 3* (t 11 = 3.21, P < 0.05) D 4 antagonist -L-745,870 (0.3 mgkg -1 ) ↓ 0.8 ± 1 (t 11 = 0.72, P = 0.49) ↓ 3.2 ± 3 (t 11 = 1.08, P = 0.30) L-745,870 (1.0 mgkg -1 ) ↓ 1.3 ± 0.4* (t 11 = 3.12, P < 0.05) ↓ 3.0 ± 1* (t 11 = 2.99, P < 0.05) L-745,870 (3.0 mgkg -1 ) ↑ 1.0 ± 1 (t 11 = 0.69, P = 0.5) ↓ 8.0 ± 2* (t 11 = 3.43, P < 0.05) *P < 0.05 significant change compared to status prior to dopamine antagonist injection This article has not been copyedited and formatted. The final version may differ from this version.
